The global xerostomia therapeutics market is expected to reach USD 796.1 million by 2025

News provided by

Nov 02, 2017, 07:12 ET

LONDON, Nov. 2, 2017 /PRNewswire/ -- Xerostomia (Dry Mouth) Therapeutics Market Analysis By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, And Segment Forecasts, 2014 - 2025

Download the full report: https://www.reportbuyer.com/product/5171140

The global xerostomia therapeutics market is expected to reach USD 796.1 million by 2025, according to a new report by Grand View Research, Inc.

Increase in favorable reimbursement policies for xerostomia products and growing awareness about associated diseases are the major factors contributing toward market growth.

In addition, increasing prevalence of xerostomia and associated diseases such as Sjogren's syndrome, diabetes, hypertension, and Parkinson's disease has a positive impact on the overall market. According to Colgate-Palmolive Company, 25 million people in the U.S. experience dry mouth. According to Sjogren Syndrome Foundation of America, around 4 million Americans are suffering from Sjogren's syndrome, an autoimmune disorder.

Growing initiatives for raising awareness about xerostomia and associated diseases are expected to drive growth. For instance, Sjogren Syndrome Foundation of America conducts awareness programs and supports patients suffering from the syndrome in the U.S. and Canada. In 2012, the foundation launched the "5-Year Breakthrough Goal" with an aim to reduce the time required to diagnose the condition to less than 2.5 years by 2017.

Furthermore, major players focus on acquiring emerging companies and conduct programs to raise awareness about dry mouth condition. For instance, Orajel, a brand of Church & Dwight Co., Inc. initiated a campaign with the help of iCrossing, a digital marketing agency to educate parents about the importance of oral care.

Further key findings from the report suggest:
• The global xerostomia (Dry Mouth) therapeutics market size was estimated at USD 602.3 million in 2016 and is expected to grow with CAGR of 3.2% from 2017 to 2025
• The OTC segment dominated the market due to factors such as ease in availability, affordability, and higher efficiency
• The dentifrices segment dominated the market in terms of revenue in 2016. Higher adoption of these products, accessibility, and affordability contribute to the dominance of the segment.
• North America held the largest share in 2016 owing to factors such as increasing prevalence of diseases resulting in dry mouth and growing initiatives for raising awareness about xerostomia
• The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increasing awareness of the disease and growing healthcare expenditure
• Some of the key players such as GlaxoSmithKline plc; Church & Dwight Co., Inc.; and Colgate-Palmolive Company dominated the global xerostomia therapeutics market in 2016

Download the full report: https://www.reportbuyer.com/product/5171140

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com